- Nov 10, 2022
Dr. Saumik Biswas, CEO and Co-Founder of Tenomix understands the need for accurate and fast cancer diagnostic tools. For him, Tenomix is a deeply personal way of honouring his aunt who passed away at an early age from improper colon cancer staging.
The Tenomix mission is to develop novel technologies that target inefficiencies in the pathology workflow, optimize cancer care, and reduce healthcare costs. In 2020, 26,900 Canadians were diagnosed with colorectal cancer, which translated to 74 Canadians being diagnosed every day. Globally, almost 2 million people were diagnosed with colorectal cancer.
Pathology staff perform the search for lymph nodes by hand, which makes the process labour, time, and resource intensive. Crucially, given the limitations of human touch, smaller lymph nodes may be missed.
The Lymphonator is Tenomix’s novel solution to this problem. A bench-top robotic scanning device that guides the hospital's pathology team in efficient and reliable lymph node identification in surgically removed colorectal cancer tissues. Through robotics and AI, the platform technology autonomously searches for LNs in surgically removed cancer tissues and replaces the existing tedious and unreliable manual search process, resulting in labour-savings, cost-savings, and increased cancer staging reliability, ultimately improving patient outcomes.
Investment Ask: $500,000